Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP
- 15 November 1985
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 232 (1), 267-271
- https://doi.org/10.1042/bj2320267
Abstract
It has been proposed that cyclic AMP inhibits platelet reactivity: by preventing agonist-induced phosphoinositide hydrolysis and the resultant formation of 1,2-diacylglycerol and elevation of cytosolic free Ca2+ concentration [(Ca2+]i); by promoting Ca2+ sequestration and/or extrusion; and by suppressing reactions stimulated by (1,2-diacylglycerol-dependent) protein kinase C and/or Ca2+-calmodulin-dependent protein kinase. We used the adenylate cyclase stimulant prostaglandin D2 to compare the sensitivity to cyclic AMP of the transduction processes (phosphoinositide hydrolysis and elevation of [Ca2+]i) and functional responses (shape change, aggregation and ATP secretion) that are initiated after agonist-receptor combination on human platelets. Prostaglandin D2 elicited a concentration-dependent elevation of platelet cyclic AMP content and inhibited platelet-activating-factor(PAF)-induced ATP secretion [I50 (concn. causing 50% inhibition) approximately 2 nM], aggregation (I50 approximately 3 nM), shape change (I50 approximately 30 nM), elevation of [Ca2+]i (I50 approximately 30 nM) and phosphoinositide hydrolysis (I50 approximately 10 nM). A 2-fold increase in cyclic AMP content resulted in abolition of PAF-induced aggregation and ATP secretion, whereas maximal inhibition of shape change, phosphoinositide hydrolysis and elevation of [Ca2+]i required a greater than 10-fold elevation of the cyclic AMP content. This differential sensitivity of the various responses to inhibition by cyclic AMP suggests that the mechanisms underlying PAF-induced aggregation and ATP secretion differ from those underlying shape change. Thus a major component of the cyclic AMP-dependent inhibition of PAF-induced platelet aggregation and ATP secretion is mediated by suppression of certain components of the activation process that occur distal to the formation of DAG or elevation of [Ca2+]i.This publication has 27 references indexed in Scilit:
- Cyclic amp inhibits platelet activation independently of its effect on cytosolic free calciumBiochemical and Biophysical Research Communications, 1985
- Tumour‐promoting phorbol esters inhibit agonist‐induced phosphatidate formation and Ca2+ flux in human plateletsFEBS Letters, 1985
- Regulation of human platelet activation—Analysis of cyclooxygenase and cyclic AMP-dependent pathwaysBiochemical Pharmacology, 1984
- Prostacyclin inhibition of phosphatidic acid synthesis in human platelets is not mediated by protein kinase CBiochemical and Biophysical Research Communications, 1984
- The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD2, PGE1, forskolin)Biochemical and Biophysical Research Communications, 1983
- Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinaseNature, 1981
- Compartmentalization of adenosine 3′:5′-monophosphate-binding proteins in human plateletsThrombosis Research, 1980
- Specific binding sites for prostaglandin D2 on human plateletsBiochemical and Biophysical Research Communications, 1979
- Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3′,5′-cyclic monophosphate and protein kinaseBiochimica et Biophysica Acta (BBA) - Biomembranes, 1977
- Formation of prostaglandin D2 during endoperoxide-induced platelet aggregationThrombosis Research, 1976